# Identification LEF1 as a Potential Novel Biomarker for Abdominal Aortic Aneurysms Based on Comprehensive Bioinformatics Analysis

**Authors:** Pan He, Xinyi Liu, Hanshen Luo, Yuehang Yang, Jiong Guo

PMC · DOI: 10.1111/jcmm.70921 · Journal of Cellular and Molecular Medicine · 2025-11-09

## TL;DR

This study identifies LEF1 as a potential new biomarker for abdominal aortic aneurysms using bioinformatics and experimental validation.

## Contribution

The novel contribution is the identification of LEF1 as a pivotal regulator and potential biomarker for AAA through integrative bioinformatics and experimental analysis.

## Key findings

- LEF1 was identified as a key gene associated with abdominal aortic aneurysms through bioinformatics analysis of GEO datasets.
- LEF1 is predominantly expressed in aortic wall-resident T cells and is linked to immune and translational regulation.
- Immunohistochemical and flow cytometry analyses confirmed elevated LEF1 expression in AAA tissues compared to controls.

## Abstract

Abdominal aortic aneurysm (AAA), a life‐threatening cardiovascular disorder, necessitates the identification of novel molecular biomarkers to facilitate early diagnosis and precision therapeutic interventions. In this study, we employed an integrative bioinformatics strategy to systematically identify and characterise a potential biomarker for AAA. By reanalyzing GEO datasets and applying Lasso regression, we identified 10 candidate genes, whose intersection with known AAA‐associated genes pinpointed LEF1 as a pivotal regulator. Single‐cell transcriptomic analysis further demonstrated that LEF1 is predominantly expressed in aortic wall‐resident T cells, suggesting a spatially restricted regulatory role. Functional enrichment analysis highlighted significant associations with MHC class II protein complex binding and ribosomal structural integrity, implicating LEF1 in immune and translational regulation. Immunohistochemical analysis demonstrated significantly elevated expression of CD3, CD4 and CD8 markers in AAA tissues compared to controls. Flow cytometry and immunofluorescence analyses confirmed LEF1 co‐localisation with both CD8+ effector T cells and CD4+ memory T cells, with significantly enhanced LEF1 expression in AAA specimens versus controls. Overall, our study systematically discovered an important hub gene LEF1, which may serve as a biomarker for AAA.

## Linked entities

- **Genes:** LEF1 (lymphoid enhancer binding factor 1) [NCBI Gene 51176], cd.3 (Cd.3 conserved hypothetical protein) [NCBI Gene 1258599], CD4 (CD4 molecule) [NCBI Gene 920], CD8A (CD8 subunit alpha) [NCBI Gene 925]

## Full-text entities

- **Genes:** LEF1 (lymphoid enhancer binding factor 1) [NCBI Gene 51176] {aka ECTD1, ECTD17, LEF-1, TCF10, TCF1ALPHA, TCF7L3}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** cardiovascular disorder (MESH:D002318), AAA (MESH:D017544)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12597617/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12597617/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12597617/full.md

---
Source: https://tomesphere.com/paper/PMC12597617